icon-folder.gif   Conference Reports for NATAP  
 
  63rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 9-12 2012
Back grey_arrow_rt.gif
 
 
 
No pharmacokinetic interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and an oral contraceptive containing ethinylestradiol and norethindrone
 
 
  Reported by Jules Levin
 
63rd Annual Meeting
of the American Association for the Study
of Liver Diseases (AASLD)
Boston, MA, USA · November 9-13, 2012
 
S Ouwerkerk-Mahadevan,1 A Simion,2 K Spittaels,2 M Peeters,2 M Beumont-Mauviel2 1Janssen Research and Development, Beerse, Belgium; 2Janssen Infectious Diseases, Beerse, Belgium

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif